Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | CDC25A | P30304 | 1/20 | 0.35 |
| ▸ | FABP6 | P51161 | 1/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 4/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20880757 | 0.74 | — | — | |
| SCHEMBL19582388 | 0.73 | ACKR3 (0.56) | ACKR3 | |
| SCHEMBL2985573 | 0.73 | PARP1 (0.54) | PARP1ACLYFABP6PARP10PARP11 | |
| SCHEMBL19582537 | 0.71 | ACKR3 (0.57) | ACKR3 | |
| SCHEMBL21999476 | 0.70 | PARP1 (0.54) | PARP1FABP6PARP10PARP11ALDH1A1 | |
| SCHEMBL20880758 | 0.70 | PARP1 (0.54) | PARP1FABP6PARP10PARP11 | |
| SCHEMBL21333792 | 0.70 | FABP6 (0.50) | PARP1FABP6PARP10PARP11 | |
| SCHEMBL19604497 | 0.69 | ALDH1A1 (0.43) | PARP1CDC25AACKR3ALDH1A1 | |
| SCHEMBL11754066 | 0.68 | ALDH1A1 (0.53) | PARP1KDM4EALDH1A1HPGD | |
| SCHEMBL2983974 | 0.67 | ALPL (0.46) | PARP1FABP6PARP10PARP11KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227263-B1 | CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-04-10 | — | — | EP | disclosed |
| US-10202368-B2 | CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2019-02-12 | — | — | US | disclosed |
| US-20170327493-A1 | CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202368-B2 | CXCR7 receptor modulators | CXCR1, CXCR5, CXCR2 | PARP1 3445/4885ACLY 3756/4885CDC25A 1350/4885 |
| US-20170327493-A1 | CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, CXCR2 | PARP1 4170/4885ACLY 3729/4885CDC25A 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.